Forefronts in Substance Abuse Disorders during Pregnancy, Postpartum, and Pediatrics (FrSADP3)

妊娠期、产后和儿科药物滥用疾病的前沿 (FrSADP3)

基本信息

批准号：
10741269
负责人：
GERALD SCHATTEN
金额：
$ 38.29万
依托单位：
MAGEE-WOMEN'S RES INST AND FOUNDATION
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-04-01 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10741269
关键词：
Address Advocate Animals Birth Career Choice Career Mobility Child Clinical Clinical Research Collaborations Color Communities Dental Development Plans Discipline of Nursing Disease Doctor of Pharmacy Doctor of Philosophy Education Educational process of instructing Ensure Environment Evaluation Faculty Fostering Future Goals Health Insurance Portability and Accountability Act Hispanic-serving Institution IACUC Indigenous American Individual Inequity Institutional Review Boards Investments Laws Leadership Medical Mentors Methods Minority-Serving Institution National Institute of Drug Abuse Participant Pediatrics Persons Pharmaceutical Preparations Postdoctoral Fellow Postpartum Period Pregnancy Psychologist Qualifying Reproducibility Research Research Personnel Research Training Resources Risk Safety Scientist Self Administration Students Substance abuse problem Supreme Court Decisions Therapeutic Toddler Training Underrepresented Minority United States National Institutes of Health Universities Vulnerable Populations Women&apos s Health addiction career design drug withdrawal education research ethical, legal, and social implication experience healthy lifestyle innovation insight lectures member minority trainee neonate peer pregnant programs responsible research conduct skill acquisition substance use translational approach

项目摘要

PROGRAM SUMMARY This proposal “Forefronts in Substance Abuse Disorders during Pregnancy, Postpartum and Pediatrics (FrSADP3)” requests its first renewal within NIDA’s Research Education Program. The primary rationale is that there are too few underrepresented minority (URM) clinicians and clinical researchers, too few clinical and research programs investigating substance use (SU) and abuse (SA), and especially, substance abuse disorders (SAD) during pregnancy, postpartum, and in pediatrics (P3); there are far too few new URM trainees for clinical and clinical research careers within the SADP3 fields. Many innovations include optimizing the depth, breadth, and scope of SAD topics of concern during and following pregnancy and the leadership and participation of Indigenous Americans. Our objectives are to train, mentor, provide meaningful research experiences for and help launch the clinical careers of SAD Clinicians and Clinical Scientists (R25 Clinical Trainees). FrSADP3 includes PI and Program Director Gerald Schatten, PhD, at Pitt and Co- I Aimee McRae- Clark, PharmD, BCPP (Addiction Research Leader), with Theresa Cronan, PhD, at SDSU (Facilitator, Psychologist, URM and Women’s Health), Calvin Simerly, PhD, at Pitt (Program Coordinator), and Evan Snyder, MD, PhD, at SBP (Addiction Neonatologist). It is overseen by a Scientific Advisory Board, 40% who are URM faculty. Five Specific Aims: I. Annual FrSADP3 advanced hands-on lab courses, offered at a URM Institution at which we provide conceptual education, expert guided discussions and research training in the methods necessary for studying pregnant people with or at risk for SAD and their neonates, toddlers, and children; relevant animals that self-administer drugs; and the mechanisms of and therapeutic strategies to alleviate the suffering from SADP3, along with research resources available at NIDA and elsewhere. II. Mentored Research into substance use and abuse disorders during pregnancy, postpartum and pediatrics, launched by the participant, together with any FrSADP3 faculty member. III. Encourage trainees’ longer-term Career Planning and gently exploring their self-identified career choices, particularly within the possibilities of them joining NIDA-NIH’s clinical and research workforce. IV. Demystify the changing regulatory oversight requirements in Responsible Conduct for Research (RCR) to ensure full compliance with the NIH’s guidance. V. Unbiased, Quantitative Independent Evaluations to track participants’ careers. The R25’s goals, then, are to provide courses in skills development, mentored addiction research, and ongoing career support resulting in comprehensive, sophisticated training in clinical and translational strategies for addressing the current challenges in addiction during pregnancy, for designing better therapies for the future, and for launching and sustaining successful careers in substance abuse, pregnancy, pediatrics, and related fields. In so doing, FrSADP3 will continue to advance the careers of the most promising clinical scientists and clinicians, with sensitivity for ensuring full diversity in the NIDA workforce.

计划概要该提案“妊娠期、产后和儿科药物滥用疾病的前沿” (FrSADP3)”要求在 NIDA 的研究教育计划中进行首次更新，其主要理由是。代表性不足的少数群体 (URM) 人群和临床研究人员太少，临床和临床研究人员太少调查物质使用（SU）和滥用（SA），特别是物质滥用的研究项目妊娠期、产后和儿科 (P3) 期间的疾病 (SAD)；新 URM 学员太少；对于 SADP3 领域的临床和临床研究职业来说，许多创新包括优化怀孕期间和怀孕后关注的 SAD 主题的深度、广度和范围以及领导力和我们的目标是培训、指导和提供有意义的研究。为 SAD 临床医生和临床科学家（R25 临床 FrSADP3 包括 Pitt and Co 的 PI 和项目总监 Gerald Schatten 博士- I Aimee McRae- Clark，药学博士，BCPP（成瘾研究领导者）与 SDSU 的 Theresa Cronan 博士（协调员， URM 和女性健康心理学家）、皮特大学 Calvin Simerly 博士（项目协调员）和 Evan Snyder，MD，PhD，SBP（成瘾新生儿学家）该委员会由科学顾问委员会监督，其中 40% 是该委员会的成员。是 URM 教师，有五个具体目标： I. 年度 FrSADP3 高级实践实验室课程，在 URM 机构，我们提供概念教育、专家指导的讨论和研究研究患有季节性情感障碍或有患季节性情感障碍风险的孕妇及其新生儿所需方法的培训，幼儿和儿童；以及自我给药的机制；减轻 SADP3 痛苦的治疗策略，以及可用的研究资源 NIDA 和其他机构指导研究怀孕期间的药物使用和滥用障碍，产后和儿科，由参与者与任何 FrSADP3 教员一起发起。鼓励学员进行更长期的职业规划，并温和地探索他们自我认同的职业选择，特别是他们有可能加入 NIDA-NIH 的临床和研究队伍 Demystify IV。负责任的研究行为 (RCR) 中不断变化的监管要求，以确保充分 V. 遵循 NIH 的指导进行公正、定量的独立评估以进行跟踪。 R25 的目标是提供技能发展、辅导成瘾方面的课程。研究和持续的职业支持，从而在临床和临床方面提供全面、复杂的培训解决当前怀孕期间成瘾挑战的转化策略，用于设计为未来提供更好的治疗方法，并在药物滥用领域开展和维持成功的职业生涯，在此过程中，FrSADP3 将继续推动妊娠、儿科和相关领域的职业发展。最有前途的临床科学家和赞助人，具有确保 NIDA 员工队伍充分多样性的敏感性。